SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending following reports that Trump is considering reclassifying marijuana, a move seen as a major catalyst for the cannabis industry. The community is buzzing about potential rallies and short squeezes, with many anticipating significant gains. Discussions also include the potential impact on other cannabis stocks and the broader implications for the sector.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending due to a mixed reaction to its earnings report; despite beating expectations and providing strong AI revenue guidance, the stock dipped as investors focused on margin concerns and a lack of specific long-term outlook. The community is debating whether this pullback is a buying opportunity or a sign of broader AI sector concerns, with many analysts reiterating bullish price targets amid the selloff.

Jiuzi Holdings, Inc. engages in franchise and operation of retail stores. The firm sells new energy vehicles (NEVs) under the brand name Jiuzi. It operates through the NEVs Sales and Franchise Services segments. The company was founded on October 10, 2019 and is headquartered in Hangzhou, China.

Jiuzi Holdings Inc

Jiuzi Holdings is trending due to news surrounding a significant commitment to expand its private placement to $1 billion, sparking discussion about potential for high gains. However, the community is also wary, with some users labeling the stock a "scam" and expressing concerns about Chinese stocks in general and potential dilution. Some traders are looking at similar stocks, hoping for a related sympathy run.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending due to community discussion around its cancer treatment pipeline, particularly after positive data in prostate cancer trials, leading to speculation about potential partnerships or a buyout. Investors believe the company is undervalued, with a high short interest creating potential for a short squeeze. The community is focused on the upcoming catalysts and continued data releases.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst ($BCRX) is trending as traders discuss the potential impact of the upcoming FDA decision on Orladeyo for pediatric patients, with some anticipating a revenue boost while others believe it's already priced in. Community members are actively debating the stock's valuation, short interest, and the potential for a buyback program to drive the price higher. The acquisition of Astria Therapeutics and the departure of a board member are also being considered as factors influencing the stock's future performance.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

FRMI is trending due to a significant drop following the termination of an agreement with its first tenant, sparking concerns about the company's data center project and future prospects; however, some investors believe the market overreacted, citing the long-term potential of AI-driven infrastructure and the company's ongoing negotiations for new tenants, while others are calling the company a scam. Community members are actively discussing potential entry points, short borrow availability, and speculating on the identity of the tenant that cancelled the agreement.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon's stock is trending after a surprising announcement that CEO Calvin McDonald will step down, coupled with better-than-expected quarterly results. The community is actively discussing the potential implications of this leadership change, along with the company's growth strategy and the impact of tariffs on margins. Investors are also reacting positively to the approval of a $1 billion increase to the stock repurchase program.

Katapult Holdings, Inc. is an e-commerce focused financial technology company. The firm is engaged in the provision of e-commerce point-of-sale lease-purchase options for nonprime U.S. consumers. It offers its customers a lease purchase transaction processing system with no long-term obligation and options for ownership. The company was founded in August 2019 and is headquartered in Plano, TX.

Katapult Holdings Inc

KPLT is trending amid discussions about a potential merger and its impact on shareholder value, as well as ongoing speculation around a possible short squeeze. Community members are actively debating the company's value after a proposed all-stock transaction and analyzing its potential for growth. The stock is also experiencing high volatility and unusual trading volume, prompting discussions about potential catalysts and market manipulation.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members rally around its positive message and potential within the Solana meme coin space. Discussions highlight its strong community, locked liquidity, and the commitment of its core team, sparking optimism for a significant run. The community emphasizes holding for long-term gains, with many believing WAGMI is coded for success on the Solana blockchain.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge to new highs, driven by a potential supply squeeze and growing industrial demand, particularly in green technologies and AI. The community is actively discussing the possibility of a sustained breakout, with some anticipating a gamma squeeze and a run to triple-digit prices, while others caution about overbought conditions and potential pullbacks. Discussions also include expectations around shifts in Fed policy and impacts on the dollar.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC...

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial PR Newswire LAUSANNE, Switzerland, Dec. 2, 2025 Company to host corporate...

Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?

Here is how ADC Therapeutics SA (ADCT) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know

ADC Therapeutics (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Zen Upgrades ADC Therapeutics (NYSE:ADCT) to "Hold"

Wall Street Zen upgraded shares of ADC Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...

FY2025 EPS Estimates for ADCT Increased by Cantor Fitzgerald

ADC Therapeutics SA (NYSE:ADCT - Free Report) - Analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for shares of ADC Therapeutics in a note issued to investors on Tuesday...

ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Expectations By $0.10 EPS

ADC Therapeutics (NYSE:ADCT - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate...

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of +25.00% and +2.03%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update PR Newswire...

FY2025 EPS Forecast for ADC Therapeutics Boosted by Analyst

ADC Therapeutics SA (NYSE:ADCT - Free Report) - Stock analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for shares of ADC Therapeutics in a research note issued...

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Adc Therapeutics SA

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

ADCT
Adc Therapeutics SA

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ADCT News

ADCTAdc Therapeutics SA